Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Syndax Pharmaceuticals, Inc.

Syndax Announces Participation in November Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Participation in September Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Participation in June Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Participation in May Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Reports First Quarter 2025 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax Announces Participation in March Investor Conferences
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
From Syndax Pharmaceuticals, Inc.
Via GlobeNewswire
Tickers SNDX
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.